Facciuto Marcelo E, Koneru Baburao, Rocca Juan P, Wolf David C, Kim-Schluger Leona, Visintainer Paul, Klein Kenneth M, Chun Hoo, Marvin Michael, Rozenblit Grigory, Rodriguez-Davalos Manuel, Sheiner Patricia A
Liver Transplant & Hepatobiliary Service, Westchester Medical Center, New York Medical College, 95 Grasslands Road, Valhalla, New York 10595, USA.
Ann Surg Oncol. 2008 May;15(5):1383-91. doi: 10.1245/s10434-008-9851-z. Epub 2008 Mar 5.
There is no clear consensus regarding the best treatment strategy for patients with advanced hepatocellular carcinoma (HCC).
Patients with cirrhosis and HCC beyond Milan who had undergone liver resection (LR) or primary orthotopic liver transplantation (OLT) between November 1995 and December 2005 were included in this study. Pathological tumor staging was based on the American Liver Tumor Study Group modified Tumor-Node-Metastasis classification.
A total of 23 HCC patients were primarily treated by means of LR, 5 of whom eventually underwent salvage OLT. An additional 32 patients underwent primary OLT. The overall actuarial survival rates at 3 and 5 years were 35% after LR, and 69% and 60%, respectively, after primary OLT. Recurrence-free survival at 5 years was significantly higher after OLT (65%) than after LR (26%). Of the patients who underwent LR, 11 (48%) experienced HCC recurrence only in the liver; 6 of these 11 presented with advanced HCC recurrence, poor medical status, or short disease-free intervals and were not considered for transplantation. Salvage OLT was performed in 5 patients with early stage recurrence (45% of patients with hepatic recurrence after LR and 22% of all patients who underwent LR). At a median of 18 months after salvage OLT, all 5 patients are alive, 4 are free of disease, and 1 developed HCC recurrence 16 months after salvage OLT.
For patients with HCC beyond Milan criteria, multimodality treatment-including LR, salvage OLT, and primary OLT-results in long-term survival in half of the patients. When indicated, LR can optimize the use of scarce donor organs by leaving OLT as a reserve option for early stage HCC recurrence.
对于晚期肝细胞癌(HCC)患者的最佳治疗策略,目前尚无明确共识。
本研究纳入了1995年11月至2005年12月期间接受肝切除术(LR)或原位肝移植术(OLT)的肝硬化且HCC超出米兰标准的患者。病理肿瘤分期基于美国肝脏肿瘤研究组改良的肿瘤-淋巴结-转移分类法。
共有23例HCC患者首先接受了LR治疗,其中5例最终接受了挽救性OLT。另有32例患者接受了原位OLT。LR后3年和5年的总体精算生存率分别为35%,原位OLT后分别为69%和60%。OLT后5年的无复发生存率(65%)显著高于LR后(26%)。接受LR的患者中,11例(48%)仅在肝脏出现HCC复发;这11例中的6例出现晚期HCC复发、身体状况差或无病间期短,未考虑进行移植。5例早期复发患者接受了挽救性OLT(LR后肝复发患者的45%,所有接受LR患者的22%)。挽救性OLT后中位18个月时,所有5例患者均存活,4例无疾病,1例在挽救性OLT后16个月出现HCC复发。
对于超出米兰标准的HCC患者,多模式治疗——包括LR、挽救性OLT和原位OLT——可使一半患者获得长期生存。在有指征时,LR可通过将OLT作为早期HCC复发的备用选择来优化稀缺供体器官的使用。